TTTS + MWFCC
The Midwest Fetal Care Center (MWFCC) performed its first fetoscopic laser ablation (FLA) for twin-twin transfusion syndrome (TTTS) in 2008. Led by a team of top medical experts in the field of maternal-fetal medicine and fetal diagnosis and therapy, our program has become one of the highest volume treatment centers for TTTS in the nation and has exceptional outcomes.
Our center performed 167 laser surgeries between July 1, 2017, and December 31, 2022, with 162 delivered and 5 ongoing pregnancies, and an overall survival rate of 87%.
Surgical Outcomes
A summary of Midwest Fetal Care Center’s current clinical outcomes data for the treatment of TTTS is presented here. Our goal is to provide our patients and community the latest TTTS patient outcomes data to support informed decision-making.
We are actively involved in research regarding TTTS and collaborate with other advanced fetal care centers in the U.S. and internationally through the North American Fetal Therapy network (NAFTnet) and the International Fetal Medicine Surgery Society (IFMSS). We submit patient data (with informed consent) to a multi-center collaborative registry hosted by NAFTnet to investigate outcomes of this procedure with the goal of advancing care of families affected by TTTS.
TTTS stage at presentation
- Stage I (%)
- Stage II (%)
- Stage III (%)
- Stage IV (%)
- TAPS
Data table
Gestational age at time of FLA
- <18 weeks (%)
- 18-19 weeks (%)
- 20-21 weeks (%)
- 22-23 weeks (%)
- 24-25 weeks (%)
- 26+ weeks (%)
Data table
Average estimated gestational age at FLA: 20 weeks, 4 days
Average estimated gestational age at delivery: 30 weeks, 6 days
Data measured July 1, 2017 – Dec. 31, 2022
Treatment Summary
Neonatal survival after TTTS fetal procedure
FLA 278 out of 319 total babies delivered
- 2 survivors (%)
- 1 survivor (%)
- 0 survivors (%)
Data table
Includes 9 triplet cases, 9 delivered: 7 cases with 3 survivors, 2 cases with 2 survivors
30-day post-delivery NICU survival rate by TTTS stage
TTTS Stage | 2 survivors | 1 survivor | 0 survivors |
---|---|---|---|
Stage I | 88% | 8% | 4% |
Stage II | 85% | 11% | 4% |
Stage III | 68% | 29% | 3% |
Stage IV | 82% | 9% | 9% |
TAPS | 83% | 17% | 0% |
Data measured July 1, 2017 – Dec. 31, 2022
We encourage you to reach out to other health care systems to request and review their outcomes data in order to utilize the information available when evaluating your health care options.
CONTACT US
Appointments and referrals
855-693-3825
(855-MW-FETAL)